Opendata, web and dolomites

GlycoMabs SIGNED

Chemoenzymatic glyco-engineering of therapeutic monoclonal antibodies

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 GlycoMabs project word cloud

Explore the words cloud of the GlycoMabs project. It provides you a very rough idea of what is the project "GlycoMabs" about.

treatment    alfc    lack    linked    containing    antibodies    conserved    glycan    domain    fucose    strategies    position    engineering    enzyme    homogenous    engineer    crystallisable    structure    mabs    basis    reactions    mediated    generate    precise    industry    fcgriiia    asn297    simplify    generation    fragment    opportunity    igg1    gained    glycoforms    biology    glycoproteins    potency    lacking    ema    approved    biosuperior    act    stablished    fucosidase    chemoenzymatic    defucosylation    protein    site    tailor    glycosylation    immune    elucidate    modulates    specificity    endos    glycoengineered    contributes    explore    learning    enzymes    skills    construct    glycoengineering    biopharmaceutical    career    structures    afucosylated    clinical    arsenal    altogether    independent    place    host    grant    antibody    therapeutic    homogeneous    glycosylated    fc    mechanisms    residue    drugs    chemical    igg    cells    me    cancer    expertise    anticancer    commercialized    affinity    excellent    laboratory    monoclonal    molecular    functions    core    mixture    effector    synthesis    structural    secondment    intersectoral    obtain    carbohydrate    active    glycomabs   

Project "GlycoMabs" data sheet

The following table provides information about the project.

Coordinator
ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOCIENCIAS 

Organization address
address: PARQUE TECNOLOGICO EDIFICIO 801 A
city: DERIO VIZCAYA
postcode: 48160
website: www.cicbiogune.es

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 160˙932 €
 EC max contribution 160˙932 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2018
 Funding Scheme MSCA-IF-EF-RI
 Starting year 2019
 Duration (year-month-day) from 2019-04-16   to  2021-04-15

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOCIENCIAS ES (DERIO VIZCAYA) coordinator 160˙932.00

Map

 Project objective

Monoclonal Antibodies (mAbs) have gained an important place in the therapeutic arsenal of anticancer drugs. mAbs are glycoproteins containing a conserved N-linked glycosylation site at residue Asn297 of the fragment crystallisable (Fc). Most of the mAbs approved by the EMA are commercialized as a complex mixture of glycoforms at this site. It is well stablished that the precise chemical structure of the N-linked glycan modulates the effector functions mediated by the Fc domain. Specifically, for cancer treatment applications, the lack of fucose on the glycan structure contributes to enhance the effector functions of the antibodies, via increased affinity of IgG1 for FcgRIIIa on immune cells. New strategies to glycoengineering mAbs with homogenous glycoforms and lacking fucose core on their glycan structures have become a priority for the biopharmaceutical industry in order to obtain “biosuperior” anticancer drugs. Here, we will engineer a novel fucosidase enzyme that can act on fully glycosylated mAbs in order to simplify the chemoenzymatic synthesis of antibody drugs, based on the host laboratory expertise in Carbohydrate Active Enzymes. We will address three specific aims: (1) to define the structural basis of EndoS antibody specificity; (2) to elucidate the molecular mechanisms of IgG defucosylation by AlfC; and (3) to engineer an enzyme with fucosidase activity and specific for IgG. The GlycoMabs project will provide me an excellent and unique career opportunity by learning new skills in structural biology, protein engineering and project management which will grant me a leading independent position. Moreover, I will explore the industry interest in the application of our novel enzymes to generate homogeneous and afucosylated antibodies through an intersectoral secondment. Altogether, we will contribute to construct the next generation of therapeutic glycoengineered mAbs to tailor the immune reactions and increase their clinical potency.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GLYCOMABS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "GLYCOMABS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

NaWaTL (2020)

Narrative, Writing, and the Teotihuacan Language: Exploring Language History Through Phylogenetics, Epigraphy and Iconography

Read More  

PNAIC (2018)

Positive and Negative Asymmetry in Intergroup Contact: Its Impact on Linguistic Forms of Communication and Physiological Responses

Read More  

MathematicsAnalogies (2019)

Mathematics Analogies

Read More